Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The company said the FDA’s written response to its Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The HARMONIC trial is a randomized, double-blind, placebo-controlled study assessing LP-300 in combination with standard chemotherapy versus chemotherapy alone in never-smoker patients with relapsed advanced lung adenocarcinoma after tyrosine kinase inhibitor (TKI) treatment. The FDA’s support for the protocol amendments marks a significant step in refining the trial design to potentially accelerate development in a patient population with high unmet need. Never-smokers with lung cancer often have distinct molecular profiles, and the focus on EGFR exon 21 L858R mutations aligns with precision medicine approaches.
Lantern Pharma is a clinical-stage precision oncology company leveraging artificial intelligence and machine learning through its proprietary RADR platform to transform cancer therapy development. The company’s clinical pipeline includes LP-184, LP-284, and LP-300, with LP-300 being the candidate under evaluation in the HARMONIC trial. Additionally, Lantern’s subsidiary Starlight Therapeutics is developing LP-184 for pediatric CNS cancers. The company also recently launched withZeta.ai, a multi-agentic AI co-scientist platform now commercially available as a subscription-based research tool, representing a new revenue stream.
The FDA’s no-objection letter provides regulatory clarity and allows Lantern to proceed with amendments that could enhance the trial’s efficiency. This development is particularly important for never-smoker NSCLC patients who have limited treatment options after TKI failure. The company’s focus on biomarker-driven patient selection reflects a broader trend in oncology toward personalized medicine, potentially improving outcomes for a subgroup that often responds differently to standard therapies.
Investors and stakeholders can access the full press release at https://ibn.fm/Rxklm and stay updated on company news at https://ibn.fm/LTRN. Lantern Pharma is headquartered in Dallas, Texas, with an AI Center of Excellence in Bengaluru, India.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Lantern Pharma Receives FDA Support for HARMONIC Trial Amendments in Never-Smoker NSCLC.